Cyxone Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cyxone şirketinin toplam hissedar öz sermayesi SEK29.6M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK33.0M ve SEK3.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 6.28m
Eşitlik	SEK 29.55m
Toplam yükümlülükler	SEK 3.46m
Toplam varlıklar	SEK 33.01m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4CX 'nin kısa vadeli varlıkları ( SEK7.0M ) kısa vadeli yükümlülüklerini ( SEK3.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4CX un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4CX borçsuzdur.

Borcun Azaltılması: 4CX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4CX son raporlanan serbest nakit akışına göre 3 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: 4CX serbest nakit akışı tahminlerine göre 3 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Cyxone Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Cyxone AB (publ) to Report Q3, 2024 Results on Nov 29, 2024

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.045 loss in 2Q 2023)

Cyxone AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.297851 million.

Cyxone AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 23.03211 million.

Cyxone AB (publ) Provides an Update on its Research and Development Program

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: €0.48

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: €0.49

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: €0.50

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - €0.71

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin